Free Trial

Taysha Gene Therapies (TSHA) Competitors

Taysha Gene Therapies logo
$5.34 +0.18 (+3.49%)
Closing price 04:00 PM Eastern
Extended Trading
$5.35 +0.01 (+0.19%)
As of 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TSHA vs. HHH, PTCT, ARWR, ACLX, KYMR, PTGX, CRNX, ZLAB, AKRO, and ACAD

Should you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Howard Hughes (HHH), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), and ACADIA Pharmaceuticals (ACAD).

Taysha Gene Therapies vs. Its Competitors

Taysha Gene Therapies (NASDAQ:TSHA) and Howard Hughes (NYSE:HHH) are related companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Howard Hughes has a net margin of 12.85% compared to Taysha Gene Therapies' net margin of -1,144.97%. Howard Hughes' return on equity of 10.51% beat Taysha Gene Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Taysha Gene Therapies-1,144.97% -78.44% -44.82%
Howard Hughes 12.85%10.51%3.15%

Taysha Gene Therapies has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Howard Hughes has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 93.8% of Howard Hughes shares are owned by institutional investors. 3.8% of Taysha Gene Therapies shares are owned by insiders. Comparatively, 48.0% of Howard Hughes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Taysha Gene Therapies$8.33M174.88-$89.30M-$0.34-15.71
Howard Hughes$1.75B2.75$200.55M$4.5717.75

Taysha Gene Therapies presently has a consensus target price of $9.00, suggesting a potential upside of 68.54%. Howard Hughes has a consensus target price of $83.33, suggesting a potential upside of 2.76%. Given Taysha Gene Therapies' higher probable upside, research analysts clearly believe Taysha Gene Therapies is more favorable than Howard Hughes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Taysha Gene Therapies
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80
Howard Hughes
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.80

In the previous week, Taysha Gene Therapies had 3 more articles in the media than Howard Hughes. MarketBeat recorded 8 mentions for Taysha Gene Therapies and 5 mentions for Howard Hughes. Howard Hughes' average media sentiment score of 0.86 beat Taysha Gene Therapies' score of 0.36 indicating that Howard Hughes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Taysha Gene Therapies
0 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Howard Hughes
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Howard Hughes beats Taysha Gene Therapies on 12 of the 16 factors compared between the two stocks.

Get Taysha Gene Therapies News Delivered to You Automatically

Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TSHA vs. The Competition

MetricTaysha Gene TherapiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.46B$4.49B$6.05B$10.51B
Dividend YieldN/A0.87%5.73%4.80%
P/E Ratio-15.7110.6785.4427.36
Price / Sales174.8823.39516.11196.40
Price / CashN/A7.0837.5761.53
Price / Book15.264.4412.426.82
Net Income-$89.30M-$134.23M$3.32B$276.89M
7 Day Performance5.53%1.24%1.01%0.27%
1 Month Performance76.82%17.66%10.75%8.31%
1 Year Performance173.85%71.72%76.19%35.60%

Taysha Gene Therapies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TSHA
Taysha Gene Therapies
2.3988 of 5 stars
$5.34
+3.5%
$9.00
+68.5%
+159.3%$1.46B$8.33M-15.71180Gap Up
HHH
Howard Hughes
2.232 of 5 stars
$85.10
+0.4%
$83.33
-2.1%
+3.4%$5.03B$1.75B18.62608
PTCT
PTC Therapeutics
3.2259 of 5 stars
$64.80
-0.9%
$69.00
+6.5%
+68.9%$5.19B$1.76B9.301,410Analyst Revision
ARWR
Arrowhead Pharmaceuticals
3.8861 of 5 stars
$37.50
+3.8%
$43.14
+15.0%
+85.7%$4.99B$3.55M-29.30400
ACLX
Arcellx
2.0028 of 5 stars
$84.38
-0.8%
$114.31
+35.5%
+0.6%$4.72B$107.94M-24.6780Analyst Revision
KYMR
Kymera Therapeutics
1.344 of 5 stars
$57.55
-0.6%
$61.26
+6.5%
+26.5%$4.14B$47.07M-16.58170Insider Trade
PTGX
Protagonist Therapeutics
1.6812 of 5 stars
$64.14
-1.1%
$68.36
+6.6%
+66.0%$4.03B$434.43M91.63120Positive News
Analyst Forecast
Insider Trade
CRNX
Crinetics Pharmaceuticals
3.7504 of 5 stars
$41.68
+2.0%
$74.45
+78.6%
-17.0%$3.85B$1.04M-10.14210
ZLAB
Zai Lab
2.7796 of 5 stars
$33.31
-1.3%
$56.35
+69.2%
+18.9%$3.77B$398.99M-16.331,869News Coverage
Positive News
AKRO
Akero Therapeutics
3.6892 of 5 stars
$46.04
-0.1%
$81.14
+76.2%
+79.3%$3.69BN/A-23.0230Insider Trade
ACAD
ACADIA Pharmaceuticals
4.5081 of 5 stars
$21.59
-1.0%
$29.12
+34.9%
+35.8%$3.68B$1.02B16.23510Analyst Forecast

Related Companies and Tools


This page (NASDAQ:TSHA) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners